piperidines and Leukemia--T-Cell

The triazinoaminopiperidine derivative S 9788 is a new multidrug-resistance modulator that is currently being evaluated in phase I clinical trials. In this study, the reversal effect of S 9788 in comparison with verapamil was shown in vitro in human T-leukemic CCRF-CEM/VLB cells expressing the multidrug-resistance (MDR) phenotype. S 9788 increased in a dose-dependent manner the cytotoxic activity of doxorubicin or vinblastine, with complete reversal of resistance occurring at 2 microM for a concomitant continuous exposure (96 h) to the cytotoxic drugs. At respective concentrations equivalent to the IC10 value (the concentration inhibiting 10% of cell growth), S 9788 was 44 times more potent than verapamil in CCRF-CEM/VLB cells. S 9788 at 2 microM did not enhance the in vitro toxicity of doxorubicin or vinblastine in the human normal bone-marrow erythroid (BFU-E) and myeloid (CFU-GM) progenitors. The effect of exposure duration and concentrations on the synergistic action of modulator and cytotoxic agent closely depended on the cytotoxic agent studied. Post-incubations with S 9788 alone after a 1-h coadministration with vinblastine and S 9788 dramatically increased the reversal effect (4-41 times) in proportion to both the duration of postincubation and the concentration of S 9788. In contrast, for doxorubicin resistance, post-incubation with S 9788 alone induced a maximal 2-fold increase in the reversal effect that was not proportional to the post-incubation duration. In patients treated with S 9788 as a 30-min intravenous infusion during phase I trials, a good correlation was found between the serum levels of S 9788 and the ability to reverse MDR in CCRF-CEM/VLB cells. The reversal effect was dose-dependent and was effective beginning at a plasma concentration of 0.25 microM. These data form a basis for the design of phase II trials using a combination of a loading dose of S 9788 given before vinblastine or doxorubicin administration followed by a maintenance infusion of S 9788 alone for a period of 2-24 h.

Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Division; Cell Line; Cell Survival; Culture Media; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Hematopoietic Stem Cells; Humans; Leukemia, T-Cell; Neoplasms; Phenotype; Piperidines; Reference Values; Triazines; Tumor Cells, Cultured; Verapamil; Vinblastine

JAK3 is a tyrosine kinase that associates with the common γ chain of cytokine receptors and is recurrently mutated in T-cell acute lymphoblastic leukemia (T-ALL). We tested the transforming properties of JAK3 pseudokinase and kinase domain mutants using in vitro and in vivo assays. Most, but not all, JAK3 mutants transformed cytokine-dependent Ba/F3 or MOHITO cell lines to cytokine-independent proliferation. JAK3 pseudokinase mutants were dependent on Jak1 kinase activity for cellular transformation, whereas the JAK3 kinase domain mutant could transform cells in a Jak1 kinase-independent manner. Reconstitution of the IL7 receptor signaling complex in 293T cells showed that JAK3 mutants required receptor binding to mediate downstream STAT5 phosphorylation. Mice transplanted with bone marrow progenitor cells expressing JAK3 mutants developed a long-latency transplantable T-ALL-like disease, characterized by an accumulation of immature CD8(+) T cells. In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosis. Our data show that JAK3 mutations are drivers of T-ALL and require the cytokine receptor complex for transformation. These results warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.

Topics: Acute Disease; Animals; Cell Transformation, Neoplastic; Disease Models, Animal; Enzyme Activation; Janus Kinase 1; Janus Kinase 3; Leukemia, T-Cell; Male; Mice; Mice, Inbred BALB C; Mutation; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; T-Lymphocytes

Various bis (3-aryl-3-oxo-propyl)methylamine hydrochlorides 1 and their corresponding structural and non-classical isomers 4-aryl-3-arylcarbonyl-1-methyl-4-piperidinols 3 were evaluated against human leukemic T (Jurkat) cells and found to possess significant cytotoxicity. Among the series 1 (bis-Mannich bases) and 3 (corresponding piperidinols), compounds la, 1c and 1e showed cytotoxic potency which was approximately 1.6, 3.7 and 3.4 times that of the reference drug 5-fluorouracil, respectively. Except for compound 1d, conversion of bis-Mannich bases to their corresponding piperidinols 3a, 3b and 3e lowered the potency. Besides chloro derivative 1d, bis-Mannich bases displayed greater cytotoxicity compared with their mono-Mannich bases, series 5. Representative bis-Mannich bases (1a, 1e) and piperidinols (3a, 3e) decreased the glutathione level of Jurkat cells. Molecular modeling was utilized in order to evaluate whether the shape, size, critical volume, solvent accessible area and partition coefficient of the different compounds had contributed to the varying potencies observed. Bis-Mannich bases 1a, 1c and 1e may serve as candidate anticancer agents for future development.

Topics: Antineoplastic Agents, Alkylating; Chemical Phenomena; Chemistry, Physical; Glutathione; Humans; Jurkat Cells; Lethal Dose 50; Leukemia, T-Cell; Mannich Bases; Methylamines; Piperidines; Structure-Activity Relationship

Various 1-arylidene-2-tetralones 1 had been shown previously to possess moderate cytotoxic properties unaccompanied by murine toxicity. The objective of the present investigation was to undertake different molecular modifications of representative members of series 1 with a view to discerning those structural features leading to increased potencies. All compounds were evaluated using human Molt 4/C8 and CEM T-lymphocytes as well as murine P388 and L1210 leukemic cells. The Mannich bases 2, 4, 5 and 7 possessed increased potencies compared to the corresponding unsaturated ketones 1 and in general were potent cytotoxics having IC50 values in the 0.2-10 microM range. QSAR using the cytotoxicity data for 2a-e suggested that potency was positively correlated with the size of the substituents in the arylidene aryl ring. Compounds 2a-f were evaluated using a panel of approximately 53 human tumour cell lines and, when all cell lines were considered, were more potent than the reference drug melphalan. In particular, marked antileukemic activity was displayed. Molecular modeling was utilized in order to evaluate whether the shapes of the different compounds contributed to the varying potencies observed. Representative compounds demonstrated minimal or no inhibiting properties towards human N-myristoyltransferase (NMT) and did not bind to calf thymus DNA. This study has revealed a number of unique lead molecules as candidate anti-neoplastic agents serving as prototypes for future development.

Topics: Acyltransferases; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Leukemia L1210; Leukemia P388; Leukemia, T-Cell; Mannich Bases; Mice; Piperidines; Structure-Activity Relationship; T-Lymphocytes; Tetralones

Human T-cell leukemia virus type I (HTLV-I) is the causative agent for adult T-cell leukemia (ATL). Molecularly, ATL cells have extensive aneugenic abnormalities that occur, at least in part, from cell cycle dysregulation by the HTLV-I-encoded Tax oncoprotein. Here, we compared six HTLV-I-transformed cells to Jurkat and primary peripheral blood mononuclear cells (PBMC) in their responses to treatment with microtubule inhibitors. We found that both Jurkat and PBMCs arrested efficiently in mitosis when treated with nocodazole. By contrast, all six HTLV-I cells failed to arrest comparably in mitosis, suggesting that ATL cells have a defect in the mitotic spindle assembly checkpoint. Mechanistically, we observed that in HTLV-I Tax-expressing cells human spindle assembly checkpoint factors hsMAD1 and hsMAD2 were mislocated from the nucleus to the cytoplasm. This altered localization of hsMAD1 and hsMAD2 correlated with loss of mitotic checkpoint function and chemoresistance to microtubule inhibitors.

Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Transformed; Cell Nucleus; Cell Survival; Cytoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; HeLa Cells; Human T-lymphotropic virus 1; Humans; Jurkat Cells; Leukemia, T-Cell; Microtubules; Mitosis; Nocodazole; Phenotype; Piperidines; Protein Binding; Spindle Apparatus; Time Factors

A series of five potential modulators of resistance were tested for their relative ability, as compared with verapamil, to sensitize CEM lymphoblastoid leukemia drug-resistant tumor sublines expressing either the classic or the atypical multidrug-resistance (MDR) phenotype to vinblastine or teniposide. Maximal non-cytotoxic concentrations of each modulator were tested and sensitization induces (SIs) were derived by comparing the drug concentration required to inhibit growth by 50% in their presence or absence. Like verapamil (10 microM) itself, three of the other modulators tested, namely, S9788 (4 microM), flunarizine (20 microM) and quinidine (30 microM), resulted in 2- to 3-fold sensitization of vinblastine against the parental CEM cells, and comparable effects were noted in the CEM/VM-1 cells, which were not cross-resistant to vinblastine. In contrast, cyclosporin A (0.5 microM) and B859-35 (2 microM) did not enhance vinblastine growth inhibition in these lines. However, the greatest sensitization with all the modulators was noted in the classic MDR VBL1000 cells, with SIs ranging from 40- to 350-fold, except for cyclosporin A, which proved ineffective at the concentration tested (SI, 2.6). The greatest extent of differential sensitization of these VBL1000 tumor cells occurred with quinidine or B859-35, which proved significantly more effective than verapamil alone. Combinations of modulators resulted in additive effects, with B859-35 plus cyclosporin A proving superior to B859-35 plus verapamil. In contrast, none of these compounds proved effective as a sensitizer to teniposide. The growth-inhibitory effects of this drug were not modified significantly in either the 92-fold teniposide-resistant VM-1 cells or in the parental cells. Addition of verapamil itself also failed to modulate teniposide growth inhibition in the VBL1000 cells, which express significant cross-resistance to this drug (36-fold). However, SI values of 3- to 5-fold were obtained using quinidine or B859-35. These results serve (a) to emphasise the need to monitor the effects of modulators not only on drug-resistant cells but also on their drug-sensitive counterparts so as to ensure differential sensitization such that normal sensitive tissues are not likely to be adversely influenced and (b) to highlight the observation that the extent of modulation differs depending not only on the antitumor drug used but also on the mechanism of drug resistance expressed. This in vitro model system

Topics: Cyclosporine; Dihydropyridines; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Flunarizine; Humans; Leukemia, T-Cell; Piperidines; Quinidine; Teniposide; Triazines; Tumor Cells, Cultured; Verapamil; Vinblastine